tradingkey.logo
tradingkey.logo

Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen® With Accelerated Speed To Therapeutic Threshold

ReutersMar 16, 2026 11:38 AM

- Nasus Pharma Ltd NSRX.A:

  • NASUS PHARMA ANNOUNCES POSITIVE TOP LINE DATA FROM PHASE 2 CLINICAL STUDY OF NS002: ACHIEVES SIGNIFICANTLY SUPERIOR AND FASTER EPINEPHRINE DELIVERY COMPARED TO EPIPEN® WITH ACCELERATED SPEED TO THERAPEUTIC THRESHOLD

  • NASUS PHARMA LTD - NS002 SHOWS FAVORABLE SAFETY PROFILE WITH NO SERIOUS ADVERSE EVENTS

  • NASUS PHARMA LTD - NS002 ACHIEVES MEDIAN T100 OF 1.69 MINUTES VERSUS 3.42 MINUTES FOR EPIPEN

  • NASUS PHARMA LTD - PIVOTAL STUDY INITIATION PLANNED FOR Q4 2026

  • NASUS PHARMA LTD - NS002 REACHES MEDIAN PEAK CONCENTRATION IN 15 MINUTES VERSUS 19.8 MINUTES FOR EPIPEN

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI